JP

Jayson Punwani

Managing Director at Abingworth

Menlo Park, California

Investor
VC

Invests in

  • Min Investment:

    $15,000,000.00

  • Max Investment:

    $30,000,000.00

  • Target Investment:

    $22,500,000.00

Skills

Venture Capital
Valuation
Due Diligence
Alternative Investments
Biotechnology
Biochemistry
Molecular Biology
Start-ups

Education

Investments

Xilio Therapeutics

Series B

Total Funding: $330M

StrideBio

Series A

Total Funding: $98M

Work Experience

Abingworth

2021

  • Managing Director

    2022

    Board director: Q32 Bio, Escient Pharmaceuticals, Addition Therapeutics

  • Partner

    2021 - 2022

    Board director: Q32 Bio

Vertuis

2021 - 2021

  • Interim CEO

    2021 - 2021

Coho Therapeutics

2019 - 2021

  • Co-founder

    2019 - 2021

Takeda Ventures, Inc.

2017 - 2020

  • Partner

    2017 - 2020

    Board director: ArmaGen (Acquired by JCR Pharma), Coho Therapeutics (co-founder), Palleon Pharma, StrideBio, VelosBio (Acquired by Merck), Xilio Therapeutics

Pappas Capital

2011 - 2017

  • Principal

    2011 - 2017

    Engaged in investment activities for a life science-focused VC firm with >$450MM in assets under management. Integral member of investment team for joint venture with Chiesi Venture Fund. Select Board observer roles: Aura Biosciences, Balance Therapeutics, CardioDx, CoLucid Pharmaceuticals, Lumena, Glycomine and OrphoMed.

The Kenan-Flagler Private Equity Fund

2010 - 2012

  • Director

    2010 - 2012

University of North Carolina at Chapel Hill

2008 - 2010

  • Technology Development @ OTD

    2009 - 2010

  • Postdoctoral Research Associate

    2008 - 2010